玻璃体腔内注射Bevacizumab联合眼底激光治疗视网膜静脉阻塞继发黄斑水肿的临床观察

doi:10.3760/cma.j.issn.1674-845X.2012.02.007

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (977 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the efficacy and safety of intravitreal injection of Bevacizumab (Avastin) combined with laser photocoagulation in the patients of macular edema secondary to retinal vein occlusion (RVO). Methods This was a retrospective cases-series study. Thirty eyes of 30 RVO patients (branch RVO 20 eyes and central RVO 10 eyes) were erolled， aged from 34 to 79， with average of （57.3±8.9）years. The eyes were treated with intravitreal injections of Bevacizumab (1.25 mg) combined with laser photocoagulation. The treatment method of intravitreal injection had been conducted according to PrONTO study. Best corrected visual acuity (BCVA， ETDRS letters)， fundus photography， optical coherence tomography （OCT） were committed at baseline and 1， 3， 6， 12 months after intravitreal injection. The ETDRS letters and the central retinal thickness (CRT) by OCT were recorded. Changes in BCVA and CRT measurements from baseline at the various follow-up endpoints were assessed with paired t test. Spearman correlation coefficient was used to measure the strength of correlation between BCVA and anatomic changes. Results The mean number of the injections in the 30 patients was 3.9±1.9. The BCVA improved 3 or more lines in 16 eyes (54%)， improved 1 to 2 lines in 10 eyes (33％)， stabilized (±1 line or no change) in 4 eyes （13%） and none decreased. The average BCVA at baseline was (42±19) letters， and improved to （60±19) letters at 12 months （t=7.87， P<0.05）. The average of retinal thickness of macular foveal decreased from (616.7±177.0)μm at baseline to (268.9±115.9)μm at 12 months (t=13.23， P<0.05). BCVA 12 months post-treatment was correlated to BCVA pre-treatment （r＝0.791， P<0.01）. Macular edema had no correlation with baseline and finally BCVA. 21 eyes (70%) showed no observed macular edema by the last follow-up and the side effects were not observed during the follow-up. Conclusion The persistent and rebound macular edema found in Bevacizumab treatment had some common characteristics in FFA. Combined intravitreal injections of Bevacizumab and laser photocoagulation therapy seemed to be effective for managing some refractory macular edema secondary to RVO. The Bevacizumab and photocoagulation related adverse events are rare.

Key words： Retinal vein occlusion Macular edema Vascular endothelial growth factor A Bavacizumb Laser therapy

Received: 05 May 2010

Fund:上海市视觉复明临床医学中心基金资助项目(FM040102)；上海市启明星追踪计划资助项目(08QH14016)

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Wen-qiu
	WANG Hong
	JIANG Yuan
	WANG Wei-jun
	ZHANG Lei
	Qian Jin
	WANG Feng-hua
	WU Ying
	SUN Xiao-dong

Cite this article:

WANG Wen-qiu,WANG Hong,JIANG Yuan等. Clinical observation of intravitreal Bevacizumab combined with laser photocoagulation for treatment of macular edema secondary to retinal vein occlusion[J]. Chinese Journal of Optometry Ophthalmology and Visual Science, 2012, 14(2): 90-94.

URL:

https://www.cjoovs.com/EN/10.3760/cma.j.issn.1674-845X.2012.02.007 OR https://www.cjoovs.com/EN/Y2012/V14/I2/90

[1]	Mitchell P， Smith W， Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol，1996，114：1243-1247.
[2]	张惠蓉，夏英杰． 407例视网膜静脉阻塞的致病危险因素和视力预后．中华眼科杂志，1991，27：271-274．
[3]	Klein R， Klein BE， Moss SE， et al. The epidemiology of retinal vein occlusion： the Beaver Dam Eye Study. Trans Am Ophthalmol Soc，2000，98：133-141.
[4]	The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology，1995，102：1425-1433.
[5]	Gregori NZ， Gaitan J， Rosenfeld PJ， et al. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. Retina，2008，28：1325-1337.
[6]	Pournaras JA， Nguyen C， Vaudaux JD， et al. Treatment of central retinal vein occlusion-related macular edema with intravitreal bevacizumab (Avastin)： preliminary results. Klin Monbl Augenheilkd，2008，225：397-400.
[7]	Rabena MD， Pieramici DJ， Castellarin AA， et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina，2007，27：419-425.
[8]	Russo V， Barone A， Conte E， et al. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina，2009，29：511-515.
[9]	Hoeh AE， Ach T， Schaal KB， et al. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol，2009，247：1635-1641.
[10]	Noma H， Funatsu H， Yamasaki M， et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol，2005，140：256-261.
[11]	Noma H， Funatsu H， Yamasaki M， et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular edema in branch retinal vein occlusion. Eye，2008， 22：42-48.
[12]	Noma H， Minamoto A， Funatsu H， et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol，2006，244：309-315.
[13]	Hloekame NM， Bouck N， Volpert O， et al. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol，2002，134：220-227.
[14]	Rosenfeld PJ， Schwartz SD， Blumenkranz MS， et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology，2005，112：1048-1053.
[15]	Rosenfeld PJ， Heier JS， Hantsbarger G， et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology，2006，113：623
[16]	Ferrara N， Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev，1997，18：4-25.
[17]	Feiner L， Barr EE， Shui YB， et al. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina，2006，26：882-888.
[18]	The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol，1997，115：486-491
[19]	Magargal LE， Kimmel AS， Sanborn GE， et al. Temporal branch retinal vein obstruction： a review. Ophthalmic Surg，1986，17：240-246.
[20]	Vujosevic S， Midena E， Pilotto E，et al. Diabetic macular edema： correlation between microperimetry and optical coherence tomography findings. Invest Ophthalmol Vis Sci，2006，47：3044-3051.
[21]	Matsumoto Y， Freund KB， Peiretti E，et al. Rebound macular edema following bevacizumab （Avastin） therapy for retinal venous occlusive disease. Retina，2007，27：426-431.
[22]	Charbel Issa P， Helb HM， Holz FG，et al. Correlation of macular function with retinal thickness in nonproliferative type 2 idiopathic macular telangiectasia. Am J Ophthalmol，2008，145：169-175.